Alder Biopharmaceuticals
ALDR
ALDR was delisted on the 21st of October, 2019.
128 hedge funds and large institutions have $595M invested in Alder Biopharmaceuticals in 2017 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 57 increasing their positions, 33 reducing their positions, and 31 closing their positions.
73% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 33
10% less funds holding
Funds holding: 142 → 128 (-14)
42% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 31
46% less capital invested
Capital invested by funds: $1.1B → $595M (-$505M)
60% less funds holding in top 10
Funds holding in top 10: 5 → 2 (-3)
96% less call options, than puts
Call options by funds: $217K | Put options by funds: $5.13M
Top Buyers
Top Sellers
ALDR Hedge Fund Activity: Q2 2017 in Review
128 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Alder Biopharmaceuticals (ALDR) for Q2 2017, worth a combined $595M — down 46% from $1.1B a quarter earlier.
Sellers outnumbered buyers: 31 funds closed out of ALDR and 18 opened new positions — a net loss of 13 holders — while 33 trimmed existing stakes and 57 added.
The largest buyer was Janus Henderson Group, opening a new position worth an estimated $59.7M. The largest seller was Fidelity Investments, cutting an estimated $34.2M.
- 128 institutional investors held Alder Biopharmaceuticals (ALDR) as of Q2 2017, down from 142 in Q1 2017.
- Funds reported $595M of Alder Biopharmaceuticals stock for Q2 2017, down 46% quarter-over-quarter.
- 18 funds opened new Alder Biopharmaceuticals positions in Q2 2017 and 31 closed out, a net change of -13 holders.
- The largest Alder Biopharmaceuticals buyer in Q2 2017 was Janus Henderson Group, an estimated $59.7M added.
- The largest Alder Biopharmaceuticals seller in Q2 2017 was Fidelity Investments, an estimated $34.2M sold.
Based on aggregated 13F filings for Q2 2017.